FWM
AXSM icon

Filbrandt Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Filbrandt Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-160
Closed -$9K – 371
2020
Q1 		$9K Buy
+160
New +$13K 0.01% 127

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Filbrandt Wealth Management's AXSM Position: Q2 2020 in Review

Filbrandt Wealth Management sold out of Axsome Therapeutics (AXSM) in Q2 2020, closing a stake of 160 shares — an estimated $9K sold.

Filbrandt Wealth Management first reported a position in AXSM in Q1 2020 and held it in 1 quarter. The position peaked at $9K in Q1 2020. 190 funds tracked by Wall St. Rank hold AXSM as of Q2 2020.

  • Filbrandt Wealth Management reported no remaining Axsome Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Filbrandt Wealth Management sold 160 Axsome Therapeutics shares in Q2 2020, an estimated $9K.
  • Filbrandt Wealth Management first reported a position in Axsome Therapeutics in Q1 2020 and held it in 1 quarter.
  • Filbrandt Wealth Management's Axsome Therapeutics position peaked at $9K in Q1 2020.
  • 190 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2020.

Based on Filbrandt Wealth Management's 13F filing for Q2 2020, filed 11 Aug 2020.